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The physiological activity of the steroid derived hormone vitamin D is regulated by several enzymatic
steps. Both 25-hydroxy vitamin D3 1a-hydroxylase (CYP27B1) and 25-hydroxyvitamin D3 24-hydroxylase
(CYP24A1) modulate blood levels of 1,25-dihydroxyvitamin D3, an activated form of vitamin D. We
previously demonstrated that CYP27B1 expression was trans-activated by sterol regulatory element
binding protein 1 (SREBP1), although whether SREBP1 also regulates CYP24A1 transcription was unclear.
Here we investigated the ability of SREBP1 to affect CYP24A1 transcription. In a luciferase reporter assay,
mouse and human CYP24A1 promoter activity was strongly activated by SREBP1 in opossum kidney
proximal tubular cells (OK-P). Three putative SREs (pSREs) were found in the mouse Cyp24a1 gene
promoter and the SREBP1 protein showed speciﬁc binding to the pSRE1 element in EMSAs. Site-directed
mutagenesis of the pSRE1 element strongly decreased SREBP1-mediated Cyp24a1 gene transcription.
Moreover, siRNA-mediated SREBP1 knock-down repressed CYP24A1 expression in human renal proximal
tubular epithelial cells (HKC-8). In animal studies, mice given various doses of thyroid hormone (T3)
showed dose-dependent reductions in renal Srebp1c and Cyp24a1 mRNA levels. Taken together, our
results suggest that SREBP1 trans-activates CYP24A1 expression through SREBP binding elements present
in the promoter.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Vitamin D regulates various biological actions such as bone
metabolism, phosphate and calcium metabolism, cellular differ-
entiation and immune systems.Most of these functions are thought
to be mediated by the vitamin D receptor (VDR), which belongs to
the nuclear receptor superfamily. 1,25-dihydroxyvitamin D3
(1,25(OH)2D3), the activated form of vitamin D, is produced throughNutrition, Faculty of Human
oto).a two-step hydroxylation. In the liver, vitamin D is ﬁrst converted to
25-hydroxyvitamin D and is subsequently modiﬁed in the kidney
by 1a-hydroxylase (CYP27B1) to form 1,25-dihydroxyvitamin D3. To
avoid effects of excess 1,25(OH)2D3, inactivation of vitamin D
modifying systems is critical. 25-hydroxyvitamin D3 24-
hydroxylase (CYP24A1) catalyzes the synthesis of 1,24,25-
trihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3, which are
inactive forms of vitamin D. CYP24A1 is expressed in the kidney,
osteoblastic cells and many other tissues to mediate systemic and
local vitamin D inactivation [1,2]. The expression of both CYP27B1
and CYP24A1 are regulated by parathyroid hormone (PTH),
1,25(OH)2D3 and ﬁbroblast growth factor-23 (FGF-23) [3,4].
We previously revealed the involvement of thyroid hormone in
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regulates 1,25(OH)2D homeostasis through negative transcriptional
regulation of CYP27B1 expression in renal proximal tubular cells.
Moreover, a sterol regulatory element (1a-SRE) that is known to the
responsive element for SRE binding protein (SREBP) was identiﬁed
in the CYP27B1 promoter. SREBP1c and SREBP1a both activate
CYP27B1 transcription [5].
SREBPs are transcriptional factors that play an important role in
lipid metabolism as master transcriptional regulators. The
mammalian genome encodes three SREBP isoforms: SREBP1c,
SREBP1a and SREBP2. Both SREBP1c and 1a are expressed from a
single gene through the use of alternative transcription start sites
that produce alternate forms of exon 1, whereas SREBP2 is encoded
by a different gene. SREBP1c preferentially enhances transcription
of genes required for fatty acid synthesis and SREBP2 preferentially
activates cholesterol synthesis. SREBP1a activates both fatty acid
and cholesterol synthesis [6,7].
Although SREBP1 is known to activate CYP27B1 transcription [5],
whether SREBP1 regulates CYP24A1 expression is unclear. Here we
investigated regulation of CYP24A1 expression by SREBP1 and
identiﬁed a novel SREBP binding element in the CYP24A1 promoter.
2. Materials and methods
2.1. Cell culture
OK-P (opossum kidney proximal tubule), HepG2 (human he-
patocellular carcinoma), HCT116 (human colorectal carcinoma) and
Saos-2 (human osteosarcoma) cells were cultured in DMEM (Dul-
becco's modiﬁed Eagle's medium; Life Technologies, Grand Island,
NY, USA). HKC-8 (human kidney proximal tubule) cells were
cultured in DMEM/Ham's F-12 (Wako, Osaka, Japan). Cell cultures
were maintained at 37 C under an atmosphere containing 5% CO2.
Growth media were supplemented with 10% or 5% fetal bovine
serum (FBS) (Life Technologies, Grand Island, NY, USA), 100 units/
ml penicillin, and 0.1mg/ml streptomycin (Sigma-Aldrich Japan,
Tokyo, Japan).
2.2. Plasmid construction
The luciferase reporter plasmid rat Fasn (Fatty acid synthase)-
Luc was previously described [8]. Plasmids carrying the human
and mouse CYP24A1 promoter (ph24A-1.49k, pm24A-960, pm24A-
217, pm24A-122, and pm24A-69) were constructed by PCR ampli-
ﬁcation using gene-speciﬁc primers (Table 1) and cloned into the
pGL4.12-basic vector (Promega KK, Tokyo, Japan) digested with
BglII. Human SREBP1c (amino acids 1e449) and human SREBP1a
(amino acids 1e473) expression plasmids in a pcDNA3.1/Myc-
His(þ) vector were constructed as previously described [8]. The
human vitamin D receptor (VDR) expression vector pSG5-VDR and
the mouse retinoid X receptor (RXR) alpha expression vector pSG5-
RXRa were previously described [9]. The plasmid pm24A-217
encoding mutated SRE1 was constructed using the QuikChangeTable 1
Oligonucleotides used in reporter plasmid construction.
Name Sequence (50 to 30)
pmCyp24A-960-Bgl-S GAAGATCTATCCAGATACAAAAGCAAG
pmCyp24A-217-Bgl-S GAAGATCTCCGGGGTGGAGTC
pmCyp24A-122-Bgl-S GAAGATCTTCCCACACCCGCCCCCCG
pmCyp24A-69-Bgl-S GAAGATCTCAGCGTGCTCATTGGCCAC
pmCyp24Aþ211-Hind-AS CCCAAGCTTGGAAGAGGCAGATGCCCAG
phCyp24A-1.49k-S GGAGATCTACATACTGTATGCAATC
phCyp24Aþ80-Bgl-AS GGAGATCTAGGGTCTGGCTGGAGCCACsite-directed mutagenesis kit (Agilent Technologies, Palo Alto, USA)
with the oligonucleotides shown in Table 3. Each plasmid was
puriﬁed using the Pure Yield Plasmid Midiprep System (Promega
KK, Tokyo, Japan).
2.3. Transfection and luciferase reporter assays
Cell transfectionswere performed using the Lipofectamine 2000
reagent (Life Technologies, Grand Island, NY, USA) as previously
described [5]. OK-P cells were transfected with 0.4 mg luciferase
reporter plasmid and 0.2 mg expression vector. The DNA/Lipofect-
amine mixtures were removed after 4 h, and the cells were grown
in DMEM containing 10% FBS and treated with 1,25(OH)2D3 (Solvay
Pharmaceuticals, Marietta, GA, USA) or ethanol vehicle for an
additional 18 h. Normalization of luciferase activity for transfection
efﬁciency was achieved by co-transfection with 0.2 mg pCMV-b
(Agilent Technologies, Palo Alto, CA, USA), a b-gal (b-galactosidase)
expression vector. Cells were harvested in cell lysis buffer (Promega
KK, Tokyo, Japan) and the lysates were assayed for luciferase ac-
tivity and b-gal activity.
2.4. Coupled transcription/translation assays
The human SREBP1c (amino acids 1e449) and human SREBP1a
(amino acids 1e473) proteins were each separately synthesized
using the TNT Quick Coupled Transcription/Translation System
(Promega KK, Tokyo, Japan) at 30 C for 90min in the presence of
20 mM methionine. The proteins were then used in electrophoretic
mobility-shift assays (EMSAs).
2.5. EMSAs
EMSAs were performed as previously described [5]. Double-
stranded oligonucleotides for mouse CYP24A1-putative SRE1
(pSRE1), pSRE2, pSRE3, pSRE1-mutant, AP-1 consensus, human
LDLR (Low density lipoprotein receptor)-SRE and rat Fasn-SRE were
synthesized (Table 2) and puriﬁed electrophoretically on 1%
agarose gels. The puriﬁed DNA fragments were end-labeled using
[g-32P] ATP (110 TBq/mmol; ICN Pharmaceuticals, Costa Mesa, CA,
USA) and T4 polynucleotide kinase (Takara Bio Inc., Shiga, Japan).
Gel shift assays were performed with 2 ml of the appropriate
in vitro-translated protein. Proteins were incubated on ice for
30min in binding buffer (20mM HEPES-KOH pH 7.9, 1mM EDTA
pH 8.0, 50mM KCl, 5% glycerol, 10mMDTT, 0.5mM PMSF) in a total
volume of 20 ml before addition of labeled probes and incubation
for 30min at room temperature. Binding reaction speciﬁcity was
determined using 100-fold molar excess of the relevant unlabeled
competitor oligonucleotide. SREBP1 components of proteineDNA
complexes were analyzed using antibodies speciﬁc for SREBP1
and c-fos (sc-8984x and sc-253x, respectively; Santa Cruz
Biotechnology, CA, USA). The incubated samples were then elec-
trophoresed on 6% (w/v) polyacrylamide gels in 0.25 TBE
(22.5mM Tris, 22.5mM boric acid, 0.5mM EDTA, pH 8.0) running
buffer for 2 h at 150 V. The gel was dried and analyzed with a
Fluorescent Image Analyzer FLA-9000 equipped with Multi-Gauge
Version 3.0 software (Fujiﬁlm, Tokyo, Japan).
2.6. RNA interference
HKC-8 cells were cultured in 35mm culture plates at 37 C un-
der an atmosphere containing 5% CO2. Upon reaching 50% conﬂu-
ence, cells were transfected. RNA mixtures containing control
siRNA (AAGUCACGACUAGAUAUUGACUUUG, CAAAGUCAAUAU-
CUAGUCGUGACUU) or 100 pmol SREBP1 siRNA (AAGACAGCA-
GAUUUAUUCAGCUUUG, CAAAGCUGAAUAAAUCUGCUGUCUU) and
Table 2
Oligonucleotide sequences used for EMSAs.
Gene Name Sense (50 to 30) Antisense (50 to 30)
mouse Cyp24a1 pSRE1 GTGTCGGTCACCCGAGGCCCC CGGGGCCTCGGGTGACCGACA
mouse Cyp24a1 pSRE2 CGGCGCCCTCACTCACCTCGCTGACTCCA ATGGAGTCAGCGAGGTGAGTGAGGGCGCC
mouse Cyp24a1 pSRE3 GGTTATCTCCGGGGTGGAGTCC TGGACTCCACCCCGGAGATAAC
mouse Cyp24a1 pSRE1 mutant GTGTCGGTTGCCCGAGGCCCC CGGGGCCTCGGGCAACCGACA
human CYP24A1 pSRE1 GCCCCGGTCACCCCAGGCCCG CCGGGCCTGGGGTGACCGGGG
human LDLR-SRE TTTGAAAATCACCCCACTGCAAACT AGTTTGCAGTGGGGTGATTTTCAAA
rat Fasn-SRE GCGCGGGCATCACCCCACCGACGGC GCCGTCGGTGGGGTGATGCCCGCGC
AP1 consensus GGCGCTTGATGACTCAGCCGGAA GGTTCCGGCTGAGTCATCAAGCG
Table 3
Oligonucleotides used in mutagenesis.
Name Sequence (50 to 30)
mouse Cyp24a1 pSRE1 mutant-S CCATGCCCTCAAGGTGTTCCACAGTCTCCC
mouse Cyp24a1 pSRE1 mutant-AS GGGAGACTGTGGAACACCTTGAGGGCATGG
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added to 50 ml serum-free media were prepared. Both solutions
were incubated for 20min at room temperature then the trans-
fectionmixtures were added to each plate containing 1.5ml serum-
free media. The siRNA/Lipofectamine mixture was removed after
4 h, and the cells were then grown for 24 h in culturemedium. After
incubation, the cells were harvested with RNAiso plus regent
(Takara Bio Inc., Shiga, Japan).
2.7. RT-PCR and real-time PCR analysis
Extraction of total RNA, cDNA synthesis, RT-PCR and real-time
PCR analysis were performed as previously described [9,10].
Brieﬂy, 2 ml cDNA was used for RT-PCR with GoTaq Green Master
Mix (Promega KK, Tokyo, Japan). The ampliﬁed PCR products were
then separated on 2% agarose gels. Real-time PCR analysis was
performed using the indicated primers (Table 4) in a Light Cycler
(Roche Diagnostics, Mannheim, Germany) and the StepOnePlus™
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).
The ampliﬁcation products were analyzed using a melting curve,
which conﬁrmed the presence of a single PCR product in all re-
actions (except for negative controls). The PCR products were
quantiﬁed by ﬁt-point analysis, and results were normalized to
those for b-actin.
2.8. Experimental animals
Seven-week-old C57BL/6 male mice were purchased from Japan
SLC, Inc. (Shizuoka, Japan). The animals were housed in pathogen-
free conditions and maintained under a standard 12-h light-dark
cycle with free access to water and standard diet ad libitum. The
experimental groups were given T3 (Sigma-Aldrich Japan, Tokyo,
Japan) by i.p. injection at 1, 5 and 20 mg/100 g body weight (n¼ 5Table 4
Oligonucleotides used for real-time PCR.
Gene Name Sense (50 to 30)
mouse b-actin CTGACCCTGAAGTACCCCATTGAACA
mouse Cyp24a1 TGCCATTCACAACTCGGACCC
mouse Srebp1c ATCGGCGCGGAAGCTGTCGGGGTAG
mouse Srebp1a GCGCCATGGACGAGCTG
human b-ACTIN GGCACCACACCTTCTACAATGAGC
human CYP24A1 GCCGTATTTAAAAGCCTGTCTGAA
human SREBP1c GGAGCCATGGATTGCACTTT
human SREBP1a GCTGCTGACCGACATCGAAper group) [5]. The animals in the control group were given a
similar volume of saline (sham-injected controls). At 24 h after
injection, all animals were sacriﬁced under pentobarbital anes-
thesia. The kidneys were rapidly removed and stored at 80 C
until analysis. All experiments involving animals were conducted in
accordance with the Guidelines for Animal Experimentation of the
Tokushima University School of Medicine.
2.9. Statistical analysis
Data are expressed as means± SD. Statistical signiﬁcance was
determined by Student's unpaired t-test or one-way ANOVA fol-
lowed by the Dunnett's post hoc test. p-values (p< 0.05) were
considered signiﬁcant.
3. Results
3.1. Transcriptional regulation of the CYP24A1 promoter by SREBP1
To determine whether SREBP1 up-regulates CYP24A1 promoter
activity, we ﬁrst constructed reporter plasmids containing mouse-
or human-derived CYP24A1 for use in luciferase reporter assays.
Both SREBP1c and SREBP1a trans-activated in each luciferase re-
porter plasmid and each SREBP1 isoform also induced trans-
activation of Fasn-Luc, a typical SREBP1 target gene (Fig. 1AeC).
In the presence of 1,25(OH)2D3, SREBP1c additively activated
pm24A-960 (Fig. 1D).
3.2. Identiﬁcation of a putative sterol regulatory element (pSRE) in
the mouse Cyp24a1 gene promoter
To identify SREBP1-responsive-elements in the CYP24A1 pro-
moter, multiple luciferase reporters with deletions in the promoter
regionwere constructed (pm24A-960, pm24A-217, pm24A-122 and
pm24A-69). SREBP1c trans-induction was remarkably decreased in
constructs that had promoter lengths shorter than 217 (Fig. 2A).
We noted three putative SRE (pSRE) sequences, pSRE1 (50-
TCACCCGAG-3': 186 to 178), pSRE2 (50-TCACCTCGCT-3': 161
to 153) and pSRE3 (50-TCCGGGGTG-3': 236 to 228) in the vi-
cinity of the proximal promoter region. Each of these pSREAntisense (50 to 30)
CTGGGGTGTTGAAGGTCTCAAACATG
TCAAGCCAGCGTTCGGGTCTAA
CGTC ACTGTCTTGGTTGTTGATGAGCTGGAGCAT
TTGGCACCTGGGCTGCT
AGCCTGGATAGCAACGTACATGGC
ACCTGGGTATTTAGCATGAGCACTG
ATGTGGCAGGAGGTGGAGAC
ATGTGGCAGGAGGTGGAGAC
Fig. 1. SREBP1 activates CYP24A1 transcription. A-C) OK-P cells were co-transfected with mouse Cyp24a1 promoter 960b (pm24A-960), human CYP24A1 promoter 1.49k (ph24A-
1.49k) or rat Fasn promoter 444b (Fasn-Luc) and pCMV-b, pcDNA3.1-SREBP1c, pcDNA3.1-SREBP1a or empty vector. Cells were incubated for 18 h prior to lysis and measurement of
b-gal and luciferase activity. D) OK-P cells were co-transfected with pm24A-960 and pCMV-b, pSG5-VDR, pSG5-RXRa, pcDNA3.1-SREBP1c or empty vector. Cells were incubated for
18 h with or without 108M 1,25(OH)2D3. Cell lysates were assayed for b-gal and luciferase activity. All data are represented as means ± SD (n¼ 2). Similar results were obtained
from two or more independent experiments.
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(Fig. 2B).
3.3. Importance of pSRE for SREBP1 binding speciﬁcity and
transcriptional induction
To show the speciﬁc binding of SREBP1 to the CYP24A1 pro-
moter, gel-shift assays were next performed. Three oligonucleo-
tides containing one of the mouse-derived pSREs were prepared.
Only pSRE1 showed band shifting (Fig. 3A). SREBP1a also showed
band shifting with pSRE1 (Fig. 3B). To conﬁrm the binding speci-
ﬁcity of SREBP1c for the mouse Cyp24a1 and human CYP24A1 oli-
gonucleotides, we also used several competitors (two consensus
SRE probes; human LDLR, rat Fasn, pSRE1 mutant oligonucleotides,
AP-1 consensus). These consensus SRE competitors inhibited
SREBP1c binding, whereas the pSRE1 mutant oligonucleotide and
AP-1 consensus had no effect. Binding speciﬁcity was conﬁrmed to
be similar using a speciﬁc antibody (Fig. 3C and D). A reporter
plasmid carrying a mutation in pSRE1 inhibited trans-induction by
SREBP1c to levels that were less than one-ﬁfth of the wild type
(Fig. 3E).
3.4. Effect of decreased SREBP1 expression on CYP24A1 mRNA levels
in vitro and in vivo
RT-PCR of endogenous mRNA expression of SREBP1c, SREBP1aand CYP24A1 in HKC8 cells showed mRNA levels that were
detectable and similar to that seen for other human-derived cell
lines (Fig. 4A). Compared with the control group, the group trans-
fected with SREBP1-speciﬁc siRNA had signiﬁcantly reduced mRNA
expression of each SREBP1 isoform and CYP24A1 (Fig. 4B).
We next examined SREBP1-mediated regulation of CYP24A1
expression in vivo. Renal mRNA levels of Srebp1c and Srebp1awere
measured in mice injected with increasing amounts of T3, which
was previously shown to negatively inhibit Cyp27b1 transcription
that in turn affects 1,25(OH)2D homeostasis [5]. T3 treatment dose-
dependently decreased Srebp1c mRNA levels (Fig. 4C), whereas
Srebp1a mRNA levels were not signiﬁcantly affected by T3 treat-
ment (Fig. 4D). Cyp24a1 mRNA levels decreased in the same
manner as Srebp1c (Fig. 4E).4. Discussion
In the current study, we demonstrated that both SREBP1 iso-
forms trans-activate CYP24A1 via a SRE element. A previous study
demonstrated that hepatic Srebp1cmRNA levels were decreased in
mice injected with T3 [11]. Furthermore, Srebp1cmRNA levels were
down-regulated in T3-treated human primary adipose tissues [12].
Here we showed that renal Srebp1c mRNA levels were speciﬁcally
and dose-dependently down-regulated in T3-treated mice (Fig. 4C).
Although the physiological role of decreases in renal Srebp1c levels
is unclear, our ﬁnding that CYP24A1 mRNA levels were repressed
Fig. 2. Identiﬁcation of a putative SRE in the CYP24A1 promoter. A) OK-P cells were co-transfected with the indicated reporter constructs and pCMV-b, pcDNA3.1-SREBP1c or empty
vector. Luciferase activity was normalized for b-gal activity. All data are represented as means± SD (n¼ 2). B) Sequence of the mouse Cyp24a1 gene promoter region corresponding
to 300 to þ47 bp containing putative (p) SRE1 (186 to 178), pSRE2 (161 to 153), pSRE3 (236 to 228), TATAbox (38 to 32), VDRE1 (170 to 156) and VDRE2
(281to 267) sequences. The homology of each pSRE in the human CYP24A1 gene promoter and consensus SRE sequence are shown below.
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Fig. 3. pSRE1 is a cis-element for SREBP1 trans-activation. A) EMSAs performed using 32P-labeled sequences containing pSRE1, pSRE2 or pSRE3 as probes with in vitro-synthesized
human SREBP1c (amino acids 1e449). B) EMSAs performed using 32P-labeled pSRE1 as probes with in vitro-synthesized human SREBP1c (amino acids 1e449) or human SREBP1a
(amino acids 1e473). C, D) EMSAs performed using 32P-labeled sequences containing mouse or human pSRE1 as probes with in vitro-synthesized human SREBP1c (amino acids
1e449). Unlabeled competitor oligonucleotides were added as indicated. A 100-fold molar excess of each competitor was used. S: Self; F: rat Fasn SRE; L: human LDLR SRE; M:
mutated mouse Cyp24a1 pSRE1; A: consensus AP1 responsive element; a1: SREBP1-speciﬁc antibody; a2: c-Fos-speciﬁc antibody. Arrows indicate the locations of the DNA-protein
complex bands. Shifted bands were separated from free probe using a 6% non-denaturing polyacrylamide gel. Representative gels are shown. NS, nonspeciﬁc band. E) Schematic
diagram showing wild-type mouse Cyp24a1 (pm24A-217) and SRE1-muated mouse Cyp24a1 (pm24A-217 mut; mutated region is marked by an X) reporter plasmid. OK-P cells were
co-transfected with either wild type or mutated Cyp24a1 reporter plasmid with pCMV-b, pcDNA3.1-SREBP1c or empty vector. Cell lysates were assayed for b-gal and luciferase
activity. All data are represented as means ± SD (n¼ 2).Similar results were obtained from two independent experiments.
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controlling levels of vitamin D metabolites in renal tissue (Fig. 4E).
Furthermore, the down-regulation of CYP24A1 mRNA levels in
siRNA-transfected HKC-8 cells indicates that changes in SREBP1
expression could affect renal Cyp24a1 levels (Fig. 4B). Interestingly,
a recent report showed that 25 (OH) vitamin D impairs SREBP
activation independently of VDR [13], indicating that levels of
vitamin D and its metabolic enzymes could regulate lipid meta-
bolism. Further studies are needed to conﬁrm the relation between
SREBP1 and vitamin D metabolism.
Here we showed that SREBP1 regulates CYP24A1 transcription.
Since CYP24A1 metabolizes 25(OH) vitamin D and 1,25(OH)2D to
inactive forms, it is notable that renal SREBP1 could regulate
CYP24A1 expression in lipogenic conditions. For instance, several
reports suggest that obese people have decreased amounts of
circulating 25 (OH) vitamin D or 1,25 (OH)2D [14e16]. Moreover,
increased renal Cyp24a1 expressionwas seen in mice fed a high-fat
diet [17]. These ﬁndings, together with those of the present study,
indicate that SREBP1 up-regulates CYP24A1 expression in several
metabolic disorders. Actually, some reports indicated that SREBP1
is associated with progressive renal diseases. Indeed, activated
renal SREBP1c induced tubule damage and glomerulosclerosis in
both diabetes mice fed a high fat diet and genetically obese animals[18e20]. Although the kidney is a crucial organ in vitamin D
metabolism, there is limited information concerning renal SREBP1
and vitamin D metabolism.
Although both SREBP1 isoforms strongly activated CYP24A1 and
Fasn-Luc transcriptional activity, SREBP1a had a more pronounced
effect than did SREBP1c (Fig. 1AeC). Because SREBP1a has a longer
N-terminal transactivation domain, its trans-activation capacity is
assumed to be stronger than that for the 1c isoform [21]. In fact, a
previous report that assessed transgenic mice overexpressing in-
dividual SREBP1 isoforms indicated that SREBP1a transgenic mice
were more susceptible to fatty liver [22]. Because SREBP1amRNA is
dominantly expressed in actively growing tissues such as thymus,
spleen and intestines [23], it is conceivable that SREBP1a act mainly
in several extra-renal organs as a local vitamin D regulator.
Results of a luciferase reporter assay using several length pro-
moters showed that speciﬁc promoter regions (217 to122) were
crucial elements in trans-induction of SREBP1 (Fig. 2A). Moreover,
we found three putative SREs in the Cyp24a1 promoter region
(Fig. 2B). Several reports indicated that SRE elements can coordi-
nate the binding elements NF-Y and Sp1 [24,25], which are thought
to be essential for the transactivation activity of SREBP1 through
formation of a co-activator complex [26]. A previous report indi-
cated that the rat Cyp24a1 promoter includes NF-Y (CCAAT
Fig. 4. Effect of SREBP1 expression on CYP24A1 mRNA levels in HKC-8 cells and mouse kidney. A) RT-PCR analysis of SREBP1c, SREBP1a and CYP24A1 mRNA levels in indicated cell
lines. B) HKC-8 cells were transfected with SREBP1 speciﬁc siRNA or control siRNA, and incubated for 24 h. SREBP1c, SREBP1a and CYP24A1 mRNA levels were determined by
quantitative PCR. b-ACTIN was used as an internal control. All data are represented as means ± SD (n¼ 9e10). C-E) C57BL/6 mice were injected i.p. with T3 (1, 5 or 20 mg/100 g body
weight) or saline (control) and killed after 24 h. Renal C) Srebp1c, D) Srebp1a, and E) Cyp24a1 mRNA levels were determined by quantitative PCR. b-actin was used as an internal
control. All data are represented as means ± SD (n¼ 5). *p< 0.05 vs. control, **p < 0.01 vs. control.
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proximal promoter region [27]. Here, 1,25(OH)2D3 additionally
increased transcriptional activity of the Cyp24a1 reporter plasmid
pm24A-960 in the presence of SREBP1c (Fig. 1D).These ﬁndings
suggest that multiple transcriptional factors including SREBP1 and
VDR cooperate in CYP24A1 promoter.
Site-directed mutagenesis of SRE1 sites was associated with
marked decreases in SREBP1c trans-induction (Fig. 3E). Moreover,
EMSA results indicated that mutated pSRE1 could not inhibit the
binding of SREBP1c to labeled probes (Fig. 3C). These results sup-
port the direct binding of SREBP1 to pSRE1 and that this binding
enhances CYP24A1 promoter activity.
In conclusion, our results revealed that SREBP1 trans-activates
CYP24A1 expression that is likely mediated through a novel
SREBP binding element within the mouse and human CYP24A1
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